Bristol-Myers Squibb reports slight increase in second-quarter sales

Share this article:

Despite increased competition from generics, Bristol-Myers Squibb (BMS) reported a slight increase in its second-quarter sales results.

Second-quarter net sales were at $4.9 billion, up 1% over the same period a year earlier.

Sales of BMS' blood thinner Plavix, the company's top-selling drug, rebounded after a generic version made by Canadian generics company Apotex briefly entered the US market late last year.

Plavix sales were up 3.8% to $1.1 billion in the second-quarter from $1.0 billion.
 
A federal court judge recently upheld Plavix's patent exclusivity until 2011.

Plavix was the No. 2 selling drug behind Pfizer's Lipitor in 2005, with global sales of $5.9 billion.  
Second-quarter sales of schizophrenia drug Abilify were up 27% to $412 million.
 
Sales of AIDS drug Reyataz were rose 7.6% to $254 million.
 
Hypertension drugs Avapro and Avalide posted a combined 6.1% increase to $297 million.
 
Meanwhile, sales of oncology drug Erbitux dropped 5.8% to $162 from $172 million a year earlier. BMS pays royalties to ImClone Systems on Erbitux. Both companies recently announced that a late-stage study of the drug in lung-cancer patients didn't meet the primary endpoint of progression-free survival.

The company's once popular cholesterol drug Pravachol, which lost patent protection in April 2006, saw its sales shrink by 59% in the second-quarter to $132 million from $323 million in the year earlier period.  

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...